Biotech & Pharma

IRA Price-Setting Has Become a Rolling, Multi-Product Revenue Override

The Inflation Reduction Act is no longer a future risk: ENBREL's Medicare Part D price took effect January 2026 (driving a 19% net selling price decline for Amgen's nine-month period), Otezla faces the same mechanism from January 2027, and Merck now states as a company expectation that Keytruda will be selected in 2027 for pricing effective January 2029. Gilead disclosed that CMS completed the Biktarvy Maximum Fair Price at a level 'substantially lower than the price we currently charge in Medicare,' effective January 2028. The GENEROUS Model's adoption by all 50 states, DC, and Puerto Rico adds a parallel Medicaid channel aligned to international benchmarks, compounding the federal mechanism across the entire commercial portfolio.

GLP-1 Demand Is Expanding Into New Pharmacological Axes and Patient Cohorts

Eli Lilly raised full-year 2026 revenue guidance to $91-92 billion, with Mounjaro and Zepbound combining for more than $16 billion in quarterly revenue, while the Medicare GLP-1 bridge program surpassed 500,000 prescriptions with 80% of enrollees classified as treatment-naive. Retatrutide Phase 3 head-to-head data showed more than double the weight loss of 2mg semaglutide, and Olora-TZP Phase 2 data showed 23.3% weight loss in type 2 diabetes patients, 57% more than tirzepatide alone. AbbVie's in-licensing of ABBV-295, an amylin analog from Gubra, and Pfizer's berobenatide expansion into knee osteoarthritis and sleep apnea confirm that the obesity pharmacotherapy market is broadening beyond GLP-1 agonism into mechanistically distinct combination and alternative approaches.

Gene Editing Crosses from Clinical Validation to Regulatory Submission

Intellia's lonvo-z BLA was accepted by the FDA with Priority Review and a March 10, 2027 PDUFA date, representing the first in vivo CRISPR therapy before the agency, with no advisory committee planned. Beam Therapeutics is targeting a risto-cel BLA submission as early as year-end 2026, the first base editing therapy to reach this stage, backed by BEACON trial data published in the New England Journal of Medicine. CRISPR Therapeutics' CTX310 one-year durability data, also published in the NEJM, showed 79% mean ANGPTL3 reduction sustained through 12 months, validating in vivo cardiovascular gene editing as a single-course intervention competitive with chronic siRNA approaches.

Large-Cap BD Has Shifted from Transformative Acquisitions to Platform Accumulation

Eli Lilly deployed $18.2 billion across seven acquisitions in the nine months ended September 30, 2026, spanning in vivo CAR-T (Kelonia), mRNA (Orna), psychedelics (AtaiBeckley), and infectious disease, while AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion and simultaneously licensed assets from RemeGen, Gubra, and Ichnos Glenmark. Pfizer explicitly shifted its BD posture from transformative to bolt-on, citing approximately $6 billion in remaining capacity after deploying approximately $80 billion across Seagen, Biohaven, and Metsera. Gilead deployed $11.5 billion in 2026 acquisitions across three distinct modalities (BCMA CAR-T, ADC, T cell engager), and Vertex agreed to acquire Crinetics for approximately $10.0 billion to enter rare endocrine disease. The pattern across tracked companies is platform accumulation across modalities rather than single-asset bets.